SEC For	rm 4																	
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL											VAL				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					ed pursuar	nt to Se		) of the	Secu	rities	s Exchan	AL OW ge Act of 14 of 1940		SHIP	Estim		er: verage burde sponse:	3235-0287 en 0.5
1. Name and Address of Reporting Person* Hege Kristen						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Mersana Therapeutics, Inc.</u> [ MRSN ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 07/03/2023								Officer below)	(give title		Other ( below)	specify
C/O MERSANA THERAPEUTICS, INC. 840 MEMORIAL DRIVE				4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) CAMBRIDGE MA 02139													Form filed by More than One Reporting Person					
(City)	y) (State) (Zip)				Ch	Rule 10b5-1(c) Transaction Indication     Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - Nor	n-Deriv	ative S	ecuri	ties Ac	quired	d, Di	spo	osed o	f, or Bei	neficiall	ly Owned	ł			
1. Title of Security (Instr. 3) 2. Trans Date (Month/I)			action Day/Year)	Execut if any	A. Deemed execution Date, any Month/Day/Year)		Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Securities Beneficiall Owned Fol Reported		Form (D) o	vnership 1: Direct r Indirect 1str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									e V	'	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s) and 4)			
		١	able II -									or Bene ble secu		Owned				
1. Title of Derivative Security (Instr. 3)	ecurity Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		4. Transactio Code (Insti 8)	n of D r. Secu Acq or D of (E	of Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	e s Illy J	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
										1			Amount		(Instr. 4)			1

Date

Exercisable

(D)

Stock Option (right to buy)	\$3.42	07/03/2023		A		3,654 <sup>(1)</sup>		(2)	07/02/2033	Common Stock	3,654	\$0	3,654	D	
Explanation of Responses:															
		anted in connection w Reporting Person pu													
2. Fully veste	ed as of the dat	e of grant.													

v (A)

Code

(-/ Alaing the Courseial	
<u>/s/ Alejandra Carvajal,</u>	07/06/2023
<u>Attorney-in-Fact</u>	<u>07700/2020</u>

Amount Number

Shares

of

Expiration Date

Title

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.